Latest Breaking News On - Neena haider - Page 2 : comparemela.com

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA). The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively. We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.

United statesNeena haiderSanjay subramanianEmmie twomblyMohamed geneadProfessor of ophthalmology at harvard medical schoolEuropean commissionSchepens eye research instituteOcugen incExchange commissionHead of corporate developmentNuclear hormone receptorsEuropean unionLeber congenitalChief executive officerRetina scientific advisory board